Trials / Recruiting
RecruitingNCT06311578
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
Phase 1 Study of Intratumoral Administration of JNJ-87704916, an Oncolytic Virus, as Monotherapy and in Combination for Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 96 (estimated)
- Sponsor
- Johnson & Johnson Enterprise Innovation Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-87704916 | JNJ-87704916 will be administered as an intratumoral injection. |
| DRUG | Cetrelimab | Cetrelimab will be administered. |
Timeline
- Start date
- 2024-04-10
- Primary completion
- 2028-11-08
- Completion
- 2032-08-26
- First posted
- 2024-03-15
- Last updated
- 2026-02-13
Locations
10 sites across 4 countries: United States, Canada, France, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06311578. Inclusion in this directory is not an endorsement.